LY3871801
18516
Phase 2 small_molecule completed
Quick answer
LY3871801 for Rheumatoid Arthritis is a Phase 2 program (small_molecule) at RIGEL PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- RIGEL PHARMACEUTICALS INC
- Indication
- Rheumatoid Arthritis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed